Turnstone Biologics Corp. (TSBX)
NASDAQ: TSBX · Real-Time Price · USD
0.454
+0.002 (0.35%)
Dec 24, 2024, 12:34 PM EST - Market closed
Company Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors.
The company’s lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.
The company was founded in 2014 and is based in LA Jolla, California.
Turnstone Biologics Corp.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 21, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Sammy Farah |
Contact Details
Address: 9310 Athena Circle, Suite 300 La Jolla, California 92037 United States | |
| Phone | 347 897 5988 |
| Website | turnstonebio.com |
Stock Details
| Ticker Symbol | TSBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001764974 |
| CUSIP Number | 90042W100 |
| ISIN Number | US90042W1009 |
| Employer ID | 83-2909368 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sammy J. Farah M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Michael F. Burgess M.D., MBChB, Ph.D. | Executive Director |
| Wendy Worcester CFA, CPA | Vice President, Principal Finance and Accounting Officer |
| Saryah Azmat | Chief Operating Officer |
| Dr. David Stojdl Ph.D. | Senior Vice President of Research and Discovery |
| Dr. Ines Verdon M.D. | Senior Vice President of Clinical Development |
| Dr. Michael Fitch Ph.D. | Senior Vice President of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |
| Jun 5, 2024 | 8-K | Current Report |
| May 31, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 13, 2024 | 10-Q | Quarterly Report |